UPTRAVI
ACTELION · SELEXIPAG
Open FDA's page for this record- Application number
- NDA207947
- Sponsor name
- ACTELION
- Submissions
- Submission type
- SUPPL
- Submission number
- 8
- Submission status
- AP
- Submission status date
- 20210130
- Review priority
- STANDARD
- Submission class code
- EFFICACY
- Submission class code description
- Efficacy
- Submission property type
- Code
- Orphan
- Application docs
- ID
- 66041
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207947s008lbl.pdf
- Date
- 20210201
- Type
- Label
- ID
- 66048
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/207947Orig1s008ltr.pdf
- Date
- 20210201
- Type
- Letter
- Submission type
- SUPPL
- Submission number
- 10
- Submission status
- AP
- Submission status date
- 20210819
- Review priority
- STANDARD
- Submission class code
- LABELING
- Submission class code description
- Labeling
- Submission property type
- Code
- Orphan
- Application docs
- ID
- 68426
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207947s010lbl.pdf
- Date
- 20210820
- Type
- Label
- ID
- 68447
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/207947Orig1s010ltr.pdf
- Date
- 20210824
- Type
- Letter
- Submission type
- SUPPL
- Submission number
- 15
- Submission status
- AP
- Submission status date
- 20260523
- Review priority
- STANDARD
- Submission class code
- LABELING
- Submission class code description
- Labeling
- Submission property type
- Code
- Orphan
- Application docs
- ID
- 86051
- Url
- https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/207947Orig1s014; s015; 214275Orig1s002ltr.pdf
- Date
- 20260527
- Type
- Letter
- ID
- 86127
- Url
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/207947Orig1s014,s015;214275Orig1s002lbl.pdf
- Date
- 20260911
- Type
- Label
- Submission type
- SUPPL
- Submission number
- 9
- Submission status
- AP
- Submission status date
- 20211025
- Review priority
- STANDARD
- Submission class code
- LABELING
- Submission class code description
- Labeling
- Submission property type
- Code
- Orphan
- Application docs
- ID
- 69114
- Url
- https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/207947Orig1s009ltr.pdf
- Date
- 20211026
- Type
- Letter
- ID
- 69121
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207947s009lbl.pdf
- Date
- 20211026
- Type
- Label
- Submission type
- SUPPL
- Submission number
- 7
- Submission status
- AP
- Submission status date
- 20190904
- Review priority
- STANDARD
- Submission class code
- LABELING
- Submission class code description
- Labeling
- Submission property type
- Code
- Orphan
- Application docs
- ID
- 59914
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/207947Orig1s007ltr.pdf
- Date
- 20190905
- Type
- Letter
- ID
- 59920
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207947s007lbl.pdf
- Date
- 20190905
- Type
- Label
- Submission type
- SUPPL
- Submission number
- 5
- Submission status
- AP
- Submission status date
- 20171220
- Review priority
- STANDARD
- Submission class code
- LABELING
- Submission class code description
- Labeling
- Submission property type
- Code
- Orphan
- Application docs
- ID
- 50845
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207947s005lbl.pdf
- Date
- 20171222
- Type
- Label
- ID
- 50906
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/207947Orig1s005ltr.pdf
- Date
- 20171227
- Type
- Letter
- Submission type
- SUPPL
- Submission number
- 3
- Submission status
- AP
- Submission status date
- 20170928
- Review priority
- STANDARD
- Submission class code
- LABELING
- Submission class code description
- Labeling
- Submission property type
- Code
- Orphan
- Application docs
- ID
- 49881
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207947s003lbl.pdf
- Date
- 20170929
- Type
- Label
- ID
- 49895
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/207947Orig1s003ltr.pdf
- Date
- 20170929
- Type
- Letter
- Submission type
- SUPPL
- Submission number
- 1
- Submission status
- AP
- Submission status date
- 20170721
- Review priority
- STANDARD
- Submission class code
- LABELING
- Submission class code description
- Labeling
- Submission property type
- Code
- Orphan
- Application docs
- ID
- 49054
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207947s001lbl.pdf
- Date
- 20170725
- Type
- Label
- ID
- 49078
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/207947Orig1s001ltr.pdf
- Date
- 20170725
- Type
- Letter
- Submission type
- ORIG
- Submission number
- 1
- Submission status
- AP
- Submission status date
- 20151221
- Review priority
- STANDARD
- Submission class code
- TYPE 1
- Submission class code description
- Type 1 - New Molecular Entity
- Submission property type
- Code
- Orphan
- Application docs
- ID
- 19976
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/2015/207947s000lbl.pdf
- Date
- 20151222
- Type
- Label
- ID
- 23043
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000TOC.html
- Date
- 20160128
- Type
- Review
- ID
- 24529
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000SumR.pdf
- Date
- 20160128
- Type
- Summary Review
- ID
- 32866
- Url
- http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/207947Orig1s000ltr.pdf
- Date
- 20151222
- Type
- Letter
- Submission type
- SUPPL
- Submission number
- 14
- Submission status
- AP
- Submission status date
- 20260523
- Review priority
- PRIORITY
- Submission class code
- EFFICACY
- Submission class code description
- Efficacy
- Submission property type
- Code
- Orphan
- Application docs
- ID
- 86050
- Url
- https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/207947Orig1s014; s015; 214275Orig1s002ltr.pdf
- Date
- 20260527
- Type
- Letter
- ID
- 86128
- Url
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/207947Orig1s014,s015;214275Orig1s002lbl.pdf
- Date
- 20260911
- Type
- Label
- Products
- Product number
- 001
- Reference drug
- Yes
- Brand name
- UPTRAVI
- Reference standard
- No
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Te code
- AB
- Active ingredients
- Name
- SELEXIPAG
- Strength
- 0.2MG
- Product number
- 008
- Reference drug
- Yes
- Brand name
- UPTRAVI
- Reference standard
- No
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Te code
- AB
- Active ingredients
- Name
- SELEXIPAG
- Strength
- 1.6MG
- Product number
- 006
- Reference drug
- Yes
- Brand name
- UPTRAVI
- Reference standard
- No
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Te code
- AB
- Active ingredients
- Name
- SELEXIPAG
- Strength
- 1.2MG
- Product number
- 004
- Reference drug
- Yes
- Brand name
- UPTRAVI
- Reference standard
- No
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Te code
- AB
- Active ingredients
- Name
- SELEXIPAG
- Strength
- 0.8MG
- Product number
- 010
- Reference drug
- Yes
- Brand name
- UPTRAVI
- Reference standard
- No
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Active ingredients
- Name
- SELEXIPAG
- Strength
- 0.1MG
- Product number
- 002
- Reference drug
- Yes
- Brand name
- UPTRAVI
- Reference standard
- Yes
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Te code
- AB
- Active ingredients
- Name
- SELEXIPAG
- Strength
- 0.4MG
- Product number
- 007
- Reference drug
- Yes
- Brand name
- UPTRAVI
- Reference standard
- No
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Te code
- AB
- Active ingredients
- Name
- SELEXIPAG
- Strength
- 1.4MG
- Product number
- 005
- Reference drug
- Yes
- Brand name
- UPTRAVI
- Reference standard
- No
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Te code
- AB
- Active ingredients
- Name
- SELEXIPAG
- Strength
- 1MG
- Product number
- 011
- Reference drug
- Yes
- Brand name
- UPTRAVI
- Reference standard
- No
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Active ingredients
- Name
- SELEXIPAG
- Strength
- 0.15MG
- Product number
- 003
- Reference drug
- Yes
- Brand name
- UPTRAVI
- Reference standard
- No
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Te code
- AB
- Active ingredients
- Name
- SELEXIPAG
- Strength
- 0.6MG
- Harmonized identifiers (openFDA)
- Application number
- NDA207947
- Brand name
- UPTRAVI, UPTRAVI TITRATION PACK
- Generic name
- SELEXIPAG
- Manufacturer name
- Actelion Pharmaceuticals US, Inc.
- Product NDC
- 66215-602, 66215-604, 66215-606, 66215-608, 66215-610, 66215-612, 66215-614, 66215-616, 66215-628, 66215-718, 66215-910, 66215-915
- Product type
- HUMAN PRESCRIPTION DRUG
- Route
- ORAL
- Substance name
- SELEXIPAG
- RxCUI
- 1729007, 1729013, 1729027, 1729029, 1729031, 1729033, 1729045, 1729047, 1729051, 1729053, 1729055, 1729057, 1729059, 1729061, 1729063, 1729065, 1729075, 1729076, 2565271, 2565275, 2744282, 2744284, 2744286, 2744288
- SPL ID
- 7c54a125-9778-41f5-b92c-181711e22e06
- SPL set ID
- a7a23b87-f892-4e2c-8e2e-ebf841220f90
- Package NDC
- 66215-602-06, 66215-602-14, 66215-604-06, 66215-606-06, 66215-608-06, 66215-610-06, 66215-612-06, 66215-614-06, 66215-616-06, 66215-628-20, 66215-718-01, 66215-910-14, 66215-915-14
- Nui
- N0000192339, N0000020068
- Pharm class epc
- Prostacyclin Receptor Agonist [EPC]
- Pharm class moa
- Prostacyclin Receptor Agonists [MoA]
- UNII
- 5EXC0E384L
